Amit Kumar Purchases 5,000 Shares of Anixa Biosciences Inc (NASDAQ:ANIX) Stock

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Anixa Biosciences Inc (NASDAQ:ANIX - Get Free Report) CEO Amit Kumar acquired 5,000 shares of the firm's stock in a transaction dated Wednesday, July 30th. The shares were purchased at an average cost of $3.16 per share, for a total transaction of $15,800.00. Following the completion of the acquisition, the chief executive officer directly owned 579,925 shares in the company, valued at approximately $1,832,563. This represents a 0.87% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Amit Kumar also recently made the following trade(s):

• On Friday, July 11th, Amit Kumar purchased 5,000 shares of Anixa Biosciences stock. The shares were bought at an average price of $3.15 per share, for a total transaction of $15,750.00.
• On Wednesday, June 4th, Amit Kumar purchased 10,000 shares of Anixa Biosciences stock. The shares were bought at an average price of $2.85 per share, for a total transaction of $28,500.00.

Anixa Biosciences Stock Performance

ANIX stock traded down $0.05 during midday trading on Friday, reaching $3.01. The company's stock had a trading volume of 44,273 shares, compared to its average volume of 108,018. The stock has a fifty day simple moving average of $3.20 and a two-hundred day simple moving average of $2.95. Anixa Biosciences Inc has a 1 year low of $2.07 and a 1 year high of $4.20. The firm has a market capitalization of $96.95 million, a price-to-earnings ratio of -7.92 and a beta of 0.43.

Anixa Biosciences (NASDAQ:ANIX - Get Free Report) last released its earnings results on Tuesday, June 3rd. The company reported ($0.09) earnings per share for the quarter, topping analysts' consensus estimates of ($0.10) by $0.01. As a group, analysts forecast that Anixa Biosciences Inc will post -0.41 EPS for the current fiscal year.

Institutional Trading of Anixa Biosciences

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Focus Partners Wealth purchased a new stake in Anixa Biosciences in the fourth quarter worth $162,000. LPL Financial LLC grew its position in shares of Anixa Biosciences by 37.2% during the 4th quarter. LPL Financial LLC now owns 42,937 shares of the company's stock worth $100,000 after buying an additional 11,633 shares in the last quarter. Jane Street Group LLC bought a new position in shares of Anixa Biosciences during the 4th quarter worth $67,000. Renaissance Technologies LLC grew its position in shares of Anixa Biosciences by 36.5% during the 4th quarter. Renaissance Technologies LLC now owns 14,573 shares of the company's stock worth $34,000 after buying an additional 3,900 shares in the last quarter. Finally, Private Advisor Group LLC bought a new position in shares of Anixa Biosciences during the 1st quarter worth $35,000. Hedge funds and other institutional investors own 29.13% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on ANIX. D. Boral Capital restated a "buy" rating and set a $10.00 price target on shares of Anixa Biosciences in a report on Tuesday, June 10th. Wall Street Zen upgraded Anixa Biosciences from a "sell" rating to a "hold" rating in a report on Friday, June 6th. One analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $9.00.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.